desloratadine (clarinex) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Desloratadine is an active, descarboethoxy metabolite of loratadine. It acts by selective inhibition of H1 histamine receptor and thus provides relief to patients with allergic rhinitis and chronic idiopathic urticaria. Desloratadine was approved by FDA and it is currently marketed under the name Clarinex (among the others).   NCATS

Chemistry

  • SMILES: ClC1=CC=C2C(CCC3=C(N=CC=C3)C2=C4CCNCC4)=C1
  • InChIKey: JAUOIFJMECXRGI-UHFFFAOYSA-N
  • Mol. Mass: 310.821
  • ALogP: 4.02
  • ChEMBL Molecule:
    desloratadine  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.3749 - $7.1768
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( desloratadine (clarinex), pseudoephedrine (Benylin) - other names: clarinex-d 12 hour, desloratadine and pseudoephedrine sulfate 24 hour )

Alternative names

8-chloro-11-piperidin-4-ylidene-6,11-dihydro-5h-benzo[5,6]cyclohepta[1,2-b]pyridine | 8-chloro-6,11-dihydro-11-(4-piperidinylidene)-5h-benzo(5,6)cyclohepta(1,2-b)pyridine | aerius | azomyr | clarinex | delopedil | descarboethoxyloratadine | descarboethoxyloratadine acetate | descarboethoxyloratidine | desloratadine | desloratadine / pseudophedrine sulphate | midetorin | neoclarityn | sch 34117 | sch-34117

Organizations (43)

Research & Development (27)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (18)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (22)

Approved Indications (3)


 

Rhinitis, Allergic, Perennial (approved 2001)

Rhinitis, Allergic, Seasonal

Urticaria

Experimental Indications - Clinical Trial Phases 1-4 (22)


 

Airway Management (Phase 4)

Asthma (Phase 4)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Chronic Urticaria (Phase 4)

Cold Temperature (Phase 3)

Conjunctivitis (Phase 3)

Conjunctivitis, Allergic (Phase 4)

Dermatitis (Phase 3)

Dermatitis, Atopic (Phase 3)

Eczema (Phase 3)

Fasting (Phase 1)

Healthy Volunteers (Phase 1)

Hypersensitivity ()

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Multiple Sclerosis, Chronic Progressive (Phase 3)

Nasal Obstruction (Phase 2)

Pruritus (Phase 3)

Rhinitis, Allergic (Phase 4)

Rhinitis, Allergic, Perennial (Phase 4)

Rhinitis, Allergic, Seasonal ()

Rhinorrhea (Phase 2)

Urticaria ()

Overview

  • Highest Phase: Phase 4
  • # of Trials: 65
  • # of Trial Organizations: 27

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue